Somewhere right now, a competitor is filing a patent. A regulator is quietly redrawing a trade corridor. A disease is shifting incidence in a market you haven't modeled yet. None of that waits for your next scheduled report and neither does Nucleus.
Nucleus isn't a login page you visit when you remember to. It's not a dashboard that goes stale the day it's published. Nucleus is the nervous system of your market strategy, a subscription-based Decision Intelligence SaaS platform that stays awake so your team doesn't have to guess.
Behind it: large-scale ETL pipelines pulling data in continuously, and 500+ human analysts making sure what reaches you is judgment, not just noise. Ahead of it: whatever decision you're about to make.
This isn't research you consult. It's intelligence you run on.
Traditional research answers "what happened." Nucleus answers "what's happening and what's next." The difference sounds small. In a launch window, a pricing decision, or an M&A play, it's the entire game.
Every dataset inside Nucleus is alive: ingested, cleaned, cross-checked, and re-validated on a continuous loop not published once and left to age quietly on a shelf. You're not buying a snapshot. You're subscribing to a heartbeat.
Think of each module less as a "feature" and more as a sense — a way Nucleus perceives the market so you don't have to piece it together yourself.
The market's vital signs — sizing, share, and forward-looking forecasts across 200+ industries, updated as the ground shifts beneath them, not after.
Disease burden across 150+ countries and 10+ therapy areas, validated by 1,000+ medical experts — because in healthcare, "close enough" isn't a strategy.
Watch pipelines move in real time across 40+ therapy areas — commercialization, regulatory timelines, and launch readiness, mapped before your competitors finish their first draft.
HS code-level trade flows and tariff shifts, tracked the moment they move — so your supply chain reacts to reality, not to last month's headlines.
Spot the gap between what the world is making and what it actually wants — country by country, sector by sector, before it becomes a shortage or a glut.
20,000+ companies under continuous watch — financials, M&A, go-to-market moves — so competitor surprises stop being surprises.
See the white space before it's filed. Patent and R&D trend tracking that turns innovation from a guessing game into a map.
When the question is too specific for a module, it's not too specific for DBMR's analysts. Bespoke research, built around your exact ask.
Clinical reality and commercial opportunity, finally in the same frame — built for teams who can't afford to look at one without the other.
It’s not a search bar with a personality. It’s the agentic layer running underneath every module in Nucleus — able to reach out to the open web, cross-reference it against DBMR's proprietary database, run the analysis herself, and hand you back exactly the format you need:
You ask the question. Sara builds the answer. While your team sleeps, the pipelines keep running, the analysts keep validating, and Sara keeps assembling — so the next time you open Nucleus, the market has already been waiting for you, not the other way around.
Reports tell you where the market stood. This is the scale that lets Nucleus tell you where it's going.
Reports tell you where the market stood. Nucleus tells you where it's going — and builds the deck to prove it.
Subscribe to Nucleus